相关临床试验
111
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1891
进行中（未招募）
7
6.3%
已完成
69
62.2%
尚未招募
4
3.6%
招募中
12
10.8%
终止
2
1.8%
Unknown
13
11.7%
撤回
4
3.6%
暂无批准数据
- A study of 833,417 patients found that people with a voice disorder but no hearing loss were 58% more likely to develop cognitive impairment or dementia than those with neither condition. - By comparison, hearing loss alone was associated with a 27% increased risk, suggesting voice disorders may be an earlier and stronger indicator of cognitive decline. - Researchers propose that vocal changes reflect breakdowns in shared neural systems and may serve as a low-cost, non-invasive screening flag for further cognitive evaluation. - The study identifies an association rather than causation, and authors call for further research into whether treating voice disorders could slow cognitive decline.
- The MELODY trial, a 300-participant randomized study, found music therapy noninferior to cognitive behavioral therapy for reducing anxiety in cancer survivors. - At week 8, music therapy reduced HADS anxiety scores by −3.12 versus −2.97 for CBT, within the noninferiority margin (P < .001), with benefits persisting at week 26. - Both interventions improved fatigue, depression, insomnia, pain, and quality of life, with minimal and comparable adverse events. - Qualitative analyses of participant-written songs revealed music therapy addresses deeper identity, relational, and existential challenges beyond episodic anxiety.
- Researchers from Drexel University and UMass Chan Medical School achieved proof-of-principle success with "silence and replace" gene therapy for SPG4, the most common form of hereditary spastic paraplegia. - The viral vector-based approach prevented nerve breakdown and symptoms in a mouse model by silencing mutated SPAST genes and replacing them with healthy versions. - The therapy successfully prevented gait defects and degenerative symptoms when administered to newborn mice before symptom onset. - Translation to human patients faces challenges including precise dosing requirements and the need for combination therapies to address existing nerve damage.
- The pivotal Bridge to HOPE clinical trial demonstrates that Hypothermic Oxygenated Perfusion (HOPE) reduces liver transplant costs by an average of $28,565 per patient compared to standard cold storage. - HOPE significantly decreased severe organ rejection rates (32% vs 67%) and steroid-resistant rejection (4% vs 43%) while shortening hospital stays by over 2 days. - The VitaSmart Perfusion System used with HOPE showed reduced complications including fewer biliary issues, re-transplants, and deaths in 12-month follow-up data. - Multiple presentations at the 2025 World Transplant Congress highlighted HOPE's clinical, economic, and immunomodulatory advantages for liver transplantation.
